NCT06965829View on ClinicalTrials.gov

The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2028

Conditions
Esophageal Cancer Stage III
Interventions
DRUG

Tislelizumab

Neoadjuvant immunotherapy (tislelizumab 200 mg d1, q3w × 2 cycles)

DRUG

Carboplatin and Paclitaxel and Radiation Therapy

Neoadjuvant chemotherapy (nad-paclitaxel 260 mg/m2 d1 + carboplatin AUC = 5 d1, q3w × 2 cycles) and node sparing radiotherapy (41.4Gy/23 times: 1.8Gy d1-5, qw × 4-5 cycles)

Trial Locations (1)

200030

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER